
Pharma companies were able to negotiate far fewer so-called ‘pay to delay’ cases as a strategy to stave off generic …

Authorities in the US claim that AbbVie and Teva filed ‘sham’ lawsuits in a complicated pay-to-delay case for generic forms …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

